TRANSTHERA-B (02617) intends to issue approximately 2.1 million shares at a discount of about 17.98%, raising approximately HK$190 million net.

TRANSTHERA-B (02617) announcement published on January 13, 2026, the company has entered into a placement agreement with the placing agent. The placing agent will use its best efforts to induce placees to purchase 2.1 million shares at a placing price of HK$92.85 per share. The placement shares represent approximately 0.69% of the total issued H shares and approximately 0.53% of the total issued shares following the completion of the placement and the issuance of new shares. The placing price of HK$92.85 per share represents a discount of approximately 17.98% from the closing price of H shares of HK$113.20 on January 13, 2026, reported on the Stock Exchange. The expected total amount of proceeds from the placement is approximately HK$195 million, with a net proceeds amounting to approximately HK$190 million. Based on this, the net issue price will be approximately HK$90.54 per share. The company plans to allocate the net proceeds from the placement as follows: approximately 60% for funding the clinical trials of the core product Tinengotinib for the treatment of Cholangiocarcinoma (CCA) in China and for the development of other indications for the core product; approximately 30% for the development of other products, including TT-00973, TT-01488, and other molecules; and approximately 10% for working capital and general corporate purposes.